Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELTX 
Elicio Therapeutics Inc. (ELTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: ELTX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.79% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 130.13M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 2 | Beta 2.08 | 52 Weeks Range 4.60 - 12.62 | Updated Date 12/3/2025 |
52 Weeks Range 4.60 - 12.62 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.61 |
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.68 | Actual -0.6 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -79.4% | Return on Equity (TTM) -60013.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 155986982 | Price to Sales(TTM) - |
Enterprise Value 155986982 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.61 | Shares Outstanding 17258652 | Shares Floating 11791647 |
Shares Outstanding 17258652 | Shares Floating 11791647 | ||
Percent Insiders 36.77 | Percent Institutions 11.74 |
Upturn AI SWOT
Elicio Therapeutics Inc.
Company Overview
History and Background
Elicio Therapeutics, founded in 2011, is a clinical-stage biotechnology company pioneering immunotherapies based on its Amphiphile (AMP) platform. They aim to improve cancer treatment by directing and amplifying immune responses directly within tumors and lymph nodes.
Core Business Areas
- AMP Platform Development: Development and refinement of the Amphiphile platform for targeted immunotherapy.
- ELi-002 2P-Targeted Vaccine: Development of a cancer vaccine targeting mKRAS mutations. Currently in clinical trials.
- ELi-004: Development of a vaccine targeting KRAS-driven cancers, in preclinical stages.
Leadership and Structure
Elicio's leadership team comprises experienced professionals in drug development, immunology, and business. The structure includes research, clinical development, and commercial divisions.
Top Products and Market Share
Key Offerings
- ELi-002 2P-Targeted Vaccine: A vaccine designed to treat cancers driven by mKRAS mutations. Currently in Phase 1/2 clinical trials. Market share is currently 0% as no product has been approved. Competitors include companies developing KRAS inhibitors and other cancer vaccines such as Mirati Therapeutics (MRTX) and Amgen (AMGN) via small molecule approach.
- AMP Platform: Elicio's proprietary Amphiphile platform, which enables targeted delivery of immunotherapeutics to lymph nodes. Currently, the AMP platform is supporting the ELi-002 2P-Targeted Vaccine. No market share exists.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cancer biology and the development of novel therapeutic approaches. Cancer vaccines and targeted immunotherapies are key areas of interest.
Positioning
Elicio is positioned as an innovator in targeted immunotherapy, leveraging its AMP platform to enhance immune responses and improve treatment outcomes. Elicio differentiates itself by directly targeting the lymph nodes.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to be in the tens of billions of dollars annually. Elicio is positioned to capture a portion of this market through its AMP platform and pipeline of targeted therapies. The mKRAS targeted market is estimated to be billions of dollars alone.
Upturn SWOT Analysis
Strengths
- Proprietary AMP platform
- Targeted immunotherapy approach
- Promising preclinical and clinical data
- Experienced management team
- Focus on difficult to treat cancers
Weaknesses
- Limited financial resources
- Single platform dependency
- Early-stage clinical development
- High regulatory hurdle
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the AMP platform to other therapeutic areas
- Positive clinical trial results
- FDA Fast Track designation
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory delays
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- MRTX
- AMGN
- BMY
- NVS
Competitive Landscape
Elicio's AMP platform offers a potentially differentiated approach to targeted immunotherapy. However, it faces competition from larger, more established pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited to the advancement of preclinical and clinical programs.
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential partnerships. Analyst estimates vary widely, reflecting the inherent risk in biotechnology.
Recent Initiatives: Recent initiatives include advancing ELi-002 through clinical trials and exploring new applications for the AMP platform.
Summary
Elicio Therapeutics is a clinical-stage biotech company with a novel AMP platform for targeted immunotherapy. The company's success hinges on the success of its clinical trials, particularly ELi-002. Potential partnerships and platform expansion represent opportunities for growth. Elicio faces threats from larger competitors and the inherent risks associated with drug development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Elicio Therapeutics Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- ClinicalTrials.gov
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Data may be dated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elicio Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-02-05 | CEO, President & Director Mr. Robert T. Connelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://elicio.com |
Full time employees 32 | Website https://elicio.com | ||
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.